Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Julphar
US Department of Justice
UBS
Healthtrust
Novartis
Deloitte
Teva
Colorcon
Merck

Generated: August 17, 2017

DrugPatentWatch Database Preview

EVOMELA Drug Profile

« Back to Dashboard

What is the patent landscape for Evomela, and when can generic versions of Evomela launch?

Evomela is a drug marketed by Spectrum Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-six patent family members in fourteen countries.

The generic ingredient in EVOMELA is melphalan hydrochloride. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.

Summary for Tradename: EVOMELA

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EVOMELA at DailyMed

Pharmacology for Tradename: EVOMELA

Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Spectrum Pharms
EVOMELA
melphalan hydrochloride
POWDER;IV (INFUSION)207155-001Mar 10, 2016RXNoNo► Subscribe► SubscribeY ► Subscribe
Spectrum Pharms
EVOMELA
melphalan hydrochloride
POWDER;IV (INFUSION)207155-001Mar 10, 2016RXNoNo► Subscribe► Subscribe► Subscribe
Spectrum Pharms
EVOMELA
melphalan hydrochloride
POWDER;IV (INFUSION)207155-001Mar 10, 2016RXNoNo► Subscribe► SubscribeY ► Subscribe
Spectrum Pharms
EVOMELA
melphalan hydrochloride
POWDER;IV (INFUSION)207155-001Mar 10, 2016RXNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: EVOMELA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,635,773Sulfoalkyl ether cyclodextrin compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EVOMELA

Country Document Number Estimated Expiration
Eurasian Patent Organization201000828► Subscribe
Japan4923144► Subscribe
Canada2771879► Subscribe
South Korea20110010742► Subscribe
Japan6039721► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Chinese Patent Office
Julphar
Citi
US Department of Justice
QuintilesIMS
Healthtrust
Moodys
Covington
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot